Twist Bioscience Corp: Form 10-Q for the period ended Mar 31, 2023
Filed with the SEC on May 8, 2023 and accepted by EDGAR at May 8, 2023, 16:19 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-01-01 to 2023-03-31 | $60.2m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 6 months2022-10-01 to 2023-03-31 | $114.4m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2023-01-01 to 2023-03-31 | $41.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2022-10-01 to 2023-03-31 | $71.1m | us-gaap:CostOfRevenue |
| Research and development | 3 months2023-01-01 to 2023-03-31 | $27.4m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-10-01 to 2023-03-31 | $58.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-01-01 to 2023-03-31 | $54.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-10-01 to 2023-03-31 | $96.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-01-01 to 2023-03-31 | −$61.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-10-01 to 2023-03-31 | −$106.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-01-01 to 2023-03-31 | $2.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2022-10-01 to 2023-03-31 | $3.0k | us-gaap:InterestExpense |
| Income tax | 3 months2023-01-01 to 2023-03-31 | $676.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-10-01 to 2023-03-31 | $752.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-01-01 to 2023-03-31 | −$59.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-10-01 to 2023-03-31 | −$101.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-01-01 to 2023-03-31 | −$1.04 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-10-01 to 2023-03-31 | −$1.78 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-01-01 to 2023-03-31 | −$1.04 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-10-01 to 2023-03-31 | −$1.78 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-01-01 to 2023-03-31 | 56,777,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-10-01 to 2023-03-31 | 56,608,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-10-01 to 2023-03-31 | −$98.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-10-01 to 2023-03-31 | $20.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-03-31 | $315.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-03-31 | $489.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-03-31 | $853.9m | us-gaap:Assets |
| Current liabilities | At period end2023-03-31 | $72.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-03-31 | $150.0m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-03-31 | $703.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-23-016426. Last ingested by Listed: Oct 27, 2026, 16:07 ET. Listed shows no prices and gives no investment advice.